TCTerrence Blaine Crowley

Terrence Blaine Crowley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Terrence Blaine Crowley has a total of 486 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cervical spinal cord compression in children and adolescents with 22q11.2 deletion syndrome

    by Jette A. Boxem, Michiel L. Houben, Malcolm L. Ecker, Erin S. Schwartz, Tom P. Schlösser, E. Zackai, T. Blaine Crowley, Aebele B. Mink van der Molen, Donna M. McDonald-McGinn, Alexander M. Tucker

  • Open Access

    Highly Inflammatory Immune Landscape in Patients With 22q11.2 Deletion Syndrome With Schizophrenia

    by Kathleen E. Sullivan, Katherine Beigel, Anne Bassett, Kelly Maurer, Nouf Alsaati, Raquel E. Gur, T. Blaine Crowley, Donna M. McDonald McGinn

    Background Schizophrenia is a severe psychiatric disorder which confers substantial morbidity and mortality. Epidemiologic data and murine models have suggested that inflammation can contribute to the etiology of schizophrenia in the general population. Chromosome 22q11.2 deletion syndrome (22q11.2DS) is the most common recognized genetic etiology for schizophrenia and is also associated with a T cell immunodeficiency. However, the relationship of the immunodeficiency to the schizophrenia is not well understood. This study defined differences in T cell populations in patients with 22q11.2DS and schizophrenia to understand immune mechanisms that might contribute to schizophrenia. Methods This study evaluated T cell populations in a cross-sectional manner. Single cell RNA-sequencing was used to define immune profiles for 46 patients with 22q11.2DS (all with standard ~3Mb LCR22A-LCR22D deletions; 10 with schizophrenia) and 18 healthy donors (controls). Main comparisons were between 22q11.2DS and control groups, and within the 22q11.2DS group, between those with and without schizophrenia. Findings Overall, patients with 22q11.2DS had an altered lymphocyte landscape compared to controls. The patients with schizophrenia exhibited expansions of T cell clones, and the expanded clones showed increased expression of genes related to inflammation and cytotoxic granule components. T cell receptors in the hyper-expanded clones differed in the patients with schizophrenia by having more self-reactive T cell receptors. Interpretation We found hyper-expanded T cell clones producing inflammatory cytokines and cytotoxic granule components in patients with 22q11.2DS and schizophrenia. The results are aligned with previous data from general population samples linking inflammation with schizophrenia. These findings facilitate the search for novel predictive markers and treatment strategies by identifying cell types producing inflammatory mediators.

  • Open Access

    Olfactory Deficits and Structural Anomalies of the Peripheral Olfactory System in 22q11.2 Deletion Syndrome

    by David R. Roalf, Donna M. McDonald McGinn, Ally Atkins, Monica E. Calkins, T. Blaine Crowley, Phoebe Freedman, R. Sean Gallagher, Christina Mastracchio, Daniel E. McGinn, Austin Moran, et al.

    Background22q11.2 deletion syndrome (22q11DS) confers approximately 25% risk for schizophrenia-spectrum disorders and shares key neurodevelopmental features with idiopathic psychosis. The olfactory system develops early in utero, providing a window into gestational disruptions relevant to psychosis risk. We hypothesized that 22q11DS would show impairments in olfactory function and structural anomalies of the olfactory system relative to typically developing controls (TD).MethodsParticipants included individuals with 22q11DS (n=101), psychosis spectrum (PS; n=56), and TD (n=52). Sinonasal symptoms (SNOT), odor identification, and discrimination (Sniffin' Sticks) were assessed behaviorally. Structural 3T MRI measured olfactory bulb volume, sulcus depth, and sulcus length. Sample sizes vary per analysis.ResultsRelative to TD, 22q11DS showed elevated sinonasal burden (p<.001), lower odor identification (p<.001), and lower odor discrimination (p<.001). PS showed elevated sinonasal burden (p<.001) and marginally lower odor identification (p=.06), but no discrimination deficit. Olfactory bulb volume was significantly smaller in 22q11DS versus TD (p=.007, r=.39); PS showed a non-significant trend (p=.07). Olfactory sulcus depth (p=.52) and length (p=.82) did not differ across groups.Conclusions22q11DS is associated with elevated sinonasal burden, robust olfactory identification and discrimination deficits substantially exceeding those of idiopathic PS, and reduced olfactory bulb volume. The co-occurrence of functional deficits and reduced bulb volume without sulcal anomalies may distinguish the 22q11DS olfactory phenotype from idiopathic psychosis, supporting partially dissociable neurodevelopmental mechanisms and the utility of 22q11DS as a genetic model for psychosis risk.

  • Open Access

    Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome

    by Jhih-Rong Lin, Daniella Miller, Dana Luong, Tanner Nelson, T. Blaine Crowley, Oanh T. Tran, Bhooma Thiruvahindrapuram, Amirhossein Hajianpour, Linda Campbell, Tiffany Busa, et al.

    Congenital heart disease (CHD) occurs in over half of individuals with 22q11.2 deletion syndrome (22q11.2DS), but lesion type varies widely. We analyzed 3,016 unrelated postnatal individuals with 22q11.2DS from specialized centers in the United States, Canada, Europe, South America, Israel, and Australia, including 1,868 with whole-genome sequencing. The typical 3 Mb LCR22 A-D deletion was present in 2,788 individuals (92.4%), with smaller A-B (n=172, 5.7%) and A-C (n=56, 1.9%) deletions comprising the remaining cohort. In multivariable mixed-effects logistic regression adjusting for sex, deletion group, genome-wide principal components (PCs), and recruitment site, four non-intercept associations, to test relationships, met study-wide FDR statistical significance. Compared with the A-B deletion, the A-D deletion was associated with lower odds of persistent truncus arteriosus (OR=0.37, 95% CI 0.18-0.75) and higher odds of isolated septal defects (OR=4.68, 95% CI 1.71-12.83), although precision was limited by the smaller A-B group. PC2 was associated with lower odds of pulmonary stenosis/atresia with additional lesions (OR=0.73, 95% CI 0.61-0.87), and PC4 with higher odds of abnormal origin of the subclavian arteries (OR=2.59, 95% CI 1.37-4.89). ADMIXTURE-derived continental ancestry proportions did not show independent associations with these two PC-associated outcomes. These lesion-specific findings suggest the hypothesis that deletion interval and broader genetic background may contribute to CHD variability in 22q11.2DS, pending future replication. KEY MESSAGES: What is already known on this topic: Chromosome 22q11.2DS is a rare genetic disorder associated with serious medical challenges. Most affected individuals have congenital heart disease but with variable phenotypic expression. One of the main questions still an open topic in the field is why individuals with 22q11.2DS show extensive phenotypic heterogeneity. What this study adds: Analysis of retrospective data on 3,016 individuals with 22q11.2DS and 1,868 with sequence data suggest that deletion type and genetic variation influence phenotypic expression of congenital heart disease. How this study might affect research, practice or policy: This work informs the clinician as to the importance of testing for deletion type and obtaining accurate cardiac phenotypes to diagnose 22q11.2DS that will improve the prognosis and disease progression. It also implicates the complexity of sex and ancestry as confounding factors that will help guide future research studies to identify genetic modifiers of congenital heart disease.


  • Open Access

    22q11.2 Deletion Syndrome in Offspring Conceived via Assisted Reproductive Technology Versus Spontaneously

    by Jennifer Borowka, Terrence Blaine Crowley, Ashika Mani, Victoria Guinta, Daniel E. McGinn, Bekah Wang, Audrey Green, Lydia Rockart, Oanh Tran, Beverly S. Emanuel, et al.

    Background/Objectives: The majority of chromosome 22q11.2 deletions are de novo, resulting from meiotic non-allelic homologous recombination (NAHR). While 22q11.2 deletion syndrome (22q11.2DS)-associated phenotypes are well characterized, risk factors leading to NAHR are poorly understood, including the possible relationship with assisted reproductive technology (ART). Here we examined the prevalence of ART conceptions and medical comorbidities in patients with 22q11.2DS vs. spontaneously conceived (SC) patients with 22q11.2DS. Methods: Retrospective analysis, under IRB approval, of medical records on 1184 patients with laboratory-confirmed de novo chromosome 22q11.2 deletions was performed. ART conceptions included IVF with and without ICSI. Deletion size and obstetric, family, and medical histories were examined. Results: We identified 30 pregnancies conceived using ART (2.57%) compared with the U.S. general population rate of 2.3% (p-value = 0.6603). ART and SC sub-cohorts demonstrated no significant differences in deletion size or perinatal outcomes, including preterm birth, multiples, polyhydramnios, or congenital heart disease. Controlling for these factors, neonates conceived via ART were more likely to be admitted to the ICU (aOR = 6.3). Conclusions: Pregnancies conceived via ART, and later found to have 22q11.2DS, demonstrated no significant differences in prevalence or perinatal outcomes compared with the U.S. general population. Moreover, NAHR is unrelated to ART in this population. Likewise, associated phenotypic features are unrelated. These data will be reassuring to those families where ART was employed to conceive children who were later found to have 22q11.2DS.

  • Open Access

    Prevalence and Spectrum of Congenital Heart Disease in Individuals With Distal Chromosome 22q11.22–23 Deletions

    by Tanner J. Nelson, Daniel E. McGinn, T. Blaine Crowley, Lydia Rockart, Audrey Green, Victoria Giunta, Oanh Tran, Daniella Miller, Jeroen Breckpot, Ann Swillen, et al.

    This study is aimed at determining the spectrum of congenital heart disease associated with distal 22q11.22–23 deletions flanked by low copy repeats, LCR22 D–H. We analyzed cardiology findings in 128 unrelated individuals with distal LCR22 D–H deletions. A total of 62 were newly described and 66 were derived from previous reports. We found that deletions which included LCR22‐D as the proximal endpoint were the most prevalent in the cohort (104/128, 81.3%). Clinically relevant congenital heart disease was identified in 48 individuals (37.5%, 95% CI 29%–46%), which is lower than the prevalence reported for typical, proximal LCR22 A–D deletions ( p = 3.7E−4), especially for conotruncal defects (13/128, 10.2%; p = 7.1E−13). Mild to moderate CHD predominated, including ventricular septal defects (22/128), bicuspid aortic valve (9/128) and mild cardiomyopathy (3/128). Persistent truncus arteriosus was the most prevalent ( n = 8/13) conotruncal heart defect, but other anomalies also occurred in singleton cases. These findings support the need for cardiac evaluation in all individuals with distal 22q11.22–23 deletions, increased use of clinical genetic testing in syndromic individuals with these findings, and molecular studies in model systems. The results demonstrate that reduced gene dosage of distal 22q11.21–23, particularly within the D–E region including MAPK1 and HIC2 convey risk for CHD.

  • ZNF280A links DNA double-strand break repair to human 22q11.2 distal deletion syndrome

    by Thomas L. Clarke, Hyo Min Cho, Ilaria Ceppi, Boya Gao, Tribhuwan Yadav, Giorgia G. Silveira, Ruben Boon, Barbara Martinez-Pastor, Nana Yaa A. Amoh, Belen Machin, et al.

    DNA double-strand breaks (DSB) are among the most deleterious forms of DNA damage and, if unresolved, result in DNA mutations and chromosomal aberrations that can cause disease, including cancer. Repair of DSBs by homologous recombination requires extensive nucleolytic digestion of DNA ends in a process known as DNA-end resection. In recent years, progress has been made in understanding how this process is initiated, but the later stages of this process—long-range DNA-end resection—are not well understood. Many questions remain in terms of how the DNA helicases and endonucleases that catalyse this process are regulated, a key step to avoiding spurious activity in the absence of breaks. The importance of DNA-end resection in human disease is highlighted by several human genetic syndromes that are caused by mutations or deficiencies in key proteins involved in this process. Here, using high-throughput microscopy coupled with a cDNA ‘chromORFeome’ library, we identified ZNF280A as an uncharacterized chromatin factor that is recruited to breaks and essential for DNA DSB repair. Lack of ZNF280A drives genomic instability and substantial sensitivity to DNA-damaging agents. Mechanistically, we demonstrate that ZNF280A promotes long-range DNA-end resection by facilitating the recruitment of the BLM–DNA2 helicase–nuclease complex to DNA DSB sites, enhancing efficiency of the enzymatic activity of this complex at DNA damage sites. ZNF280A is therefore essential for DNA-end resection and DNA repair by homologous recombination. Importantly, ZNF280A is hemizygously deleted in a human genetic condition, 22q11.2 distal deletion syndrome. Features of this condition include congenital heart disease, microcephaly, immune deficiency, developmental delay and cognitive deficits—features that are associated with other human syndromes caused by defects in genes involved in DNA repair. Remarkably, cells from individuals with a 22q11.2 distal deletion have defects in DNA-end resection and homologous recombination, resulting in increased incidence of genomic instability. These phenotypes are rescued by reintroduction of ZNF280A, providing evidence of defective DNA repair as a potential mechanistic explanation for several clinical features associated with this human condition.


  • Open Access

    Neurocognitive profiles of 22q11.2 and 16p11.2 deletions and duplications

    by Ruben C. Gur, Carrie E. Bearden, Sebastien Jacquemont, Ann Swillen, Therese van Amelsvoort, Marianne van Den Bree, Jacob Vorstman, Jonathan Sebat, Kosha Ruparel, Robert Sean Gallagher, et al.

    Rare recurrent copy number variants (CNVs) at chromosomal loci 22q11.2 and 16p11.2 are genetic disorders with lifespan risk for neuropsychiatric disorders. Microdeletions and duplications are associated with neurocognitive deficits, yet few studies compared these groups using the same measures to address confounding measurement differences. We report a prospective international collaboration applying the same computerized neurocognitive assessment, the Penn Computerized Neurocognitive Battery (CNB), administered in a multi-site study on rare genomic disorders: 22q11.2 deletions (n = 492); 22q11.2 duplications (n = 106); 16p11.2 deletion (n = 117); and 16p11.2 duplications (n = 46). Domains examined include executive functions, episodic memory, complex cognition, social cognition, and psychomotor speed. Accuracy and speed for each domain were included as dependent measures in a mixed-model repeated measures analysis. Locus (22q11.2, 16p11.2) and Copy number (deletion/duplication) were grouping factors and Measure (accuracy, speed) and neurocognitive domain were repeated measures factors, with Sex and Site as covariates. We also examined correlation with IQ. We found a significant Locus × Copy number × Domain × Measure interaction (p = 0.0004). 22q11.2 deletions were associated with greater performance accuracy deficits than 22q11.2 duplications, while 16p11.2 duplications were associated with greater specific deficits than 16p11.2 deletions. Duplications at both loci were associated with reduced speed compared to deletions. Performance profiles differed among the groups with particularly poor memory performance of the 22q11.2 deletion group while the 16p11.2 duplication group had greatest deficits in complex cognition. Average accuracy on the CNB was moderately correlated with Full Scale IQ. Deletions and duplications of 22q11.2 and 16p11.2 have differential effects on accuracy and speed of neurocognition indicating locus specificity of performance profiles. These profile differences can help inform mechanistic substrates to heterogeneity in presentation and outcome, and can only be established in large-scale international consortia using the same neurocognitive assessment. Future studies could aim to link performance profiles to clinical features and brain function.


  • Open Access

    Expanding Genetic Counselor Roles: A Model for Global Research Development

    by Colleen C. Muraresku, Elizabeth M. McCormick, Lydia Rockart, T. Blaine Crowley, Stephanie Asher, Amanda Back, Sarah M. Baldino, Emma Bedoukian, Allison D. Britt, Natalie Burrill, et al.

    Purpose: Genetic counselors (GCs) increasingly play key roles in advancing genomic medicine through innovative research. Here, we examine one large cohort of GCs’ evolving contributions to the literature, with the goal of facilitating worldwide professional development for GCs through scholarly activities. Methods: Publications were cataloged by members of the Section of Genetic Counseling (Section), established at the Children’s Hospital of Philadelphia and the University of Pennsylvania in 2014, including publication year, journal, impact factor, and author position. Data were organized using the “My Bibliography” tool on the National Center for Biotechnology Information website and a Research Electronic Data Capture database created to initially collect manuscripts published through 30 June 2020. A subsequent survey captured publications through 5 February 2024. Results: An amount of 52 of 120 (43%) GCs shared their curriculum vitae/papers. 992 unique publications were identified from 1986 to 2024. Since 2013, no less than 32 papers were published annually by Section members and no less than 10 GCs contributed to publications yearly. Impact factors typically averaged >5.0 per year. Areas of foci diversified considerably since 2015. Conclusions: Here, we establish that GCs indeed contribute to scholarly work as evidenced by the number of publications alone. The establishment of an academic home may have contributed, given publications increased concurrent to launching the Section, providing a model for organizing GCs at institutions nationally and internationally. Highlighting such achievements will foster the expansion of GC roles in the era of precision genomic medicine and therapy. Considering ways to support GCs towards expanding these activities is equally important.


  • Risk of meningomyelocele mediated by the common 22q11.2 deletion

    by Keng Ioi Vong, Sangmoon Lee, Kit Sing Au, T. Blaine Crowley, Valeria Capra, Jeremiah Martino, Meade Haller, Camila Araújo, Renee George, Bryn Gerding, et al.

    Meningomyelocele is one of the most severe forms of neural tube defects (NTDs) and the most frequent structural birth defect of the central nervous system. We assembled the Spina Bifida Sequencing Consortium to identify causes. Exome and genome sequencing of 715 parent-offspring trios identified six patients with chromosomal 22q11.2 deletions, suggesting a 23-fold increased risk compared with the general population. Furthermore, analysis of a separate 22q11.2 deletion cohort suggested a 12- to 15-fold increased NTD risk of meningomyelocele. The loss of Crkl , one of several neural tube–expressed genes within the minimal deletion interval, was sufficient to replicate NTDs in mice, where both penetrance and expressivity were exacerbated by maternal folate deficiency. Thus, the common 22q11.2 deletion confers substantial meningomyelocele risk, which is partially alleviated by folate supplementation.